A new market study, titled “ Global Eye Cancer Market Research Report- Forecast till 2023”been featured on WiseGuyReports.October 22, 2020

Report Description

This report analyzes the global eye cancer market by type (intraocular cancer, squamous cell cancer, rhabdomyosarcoma), treatment (chemotherapy, targeted therapy, surgery & radiation therapy, hormone therapy), end user (hospital & clinics); it also studies the top manufacturers in the market.

The global eye cancer market is expected to grow at a CAGR of approximately 8.3 % during the forecast period 2017-2023.

The major players in global eye cancer market include:

• Novartis AG (Switzerland)

• Spectrum Pharmaceuticals Inc. (U.S.)

• GlaxoSmithKline Plc. (U.K.)

• Bayer AG (Germany)

• Amgen, Inc. (U.S.)

• Bristol-Myers Squibb Company (U.S.)

• Eli Lilly and Company (U.S.)

• AstraZeneca Plc. (U.K.)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Janssen Biotech, Inc. (U.S.)

• Sanofi (France)

• AbbVie Inc. (U.S.)

• Takeda Pharmaceuticals (Japan)

• Pfizer, Inc. (U.S.)

• Merck & Co., Inc. (U.S.)

• Oncomed Pharmaceuticals (U.S.)

• Immunomedics (U.S.)

The market revenue and share have been analyzed with respect to the following regions and countries:

Americas

North America

U.S.

Canada

South America

Europe

Western Europe

Germany

France

Italy

Spain

U.K.

Rest of Western Europe

Eastern Europe

Asia Pacific

Japan

China

India

Australia

Republic of Korea

Rest of Asia Pacific

The Middle East & Africa

United Arab Emirates

Saudi Arabia

Oman

Kuwait

Qatar

Rest of Middle East & Africa

ALSO READ https://industrytoday.co.uk/health_and_safety/eye-cancer-industry--...

On the basis of type, the global eye cancer market has been categorized into the following segments:

• Intraocular Cancer

• Squamous Cell Cancer

• Rhabdomyosarcoma

On the basis of treatment, the global eye cancer market has been categorized into the following segments:

• Chemotherapy

• Targeted Therapy

• Surgery & Radiation Therapy

• Hormone Therapy

On the basis of end user, the global eye cancer market has been categorized into the following segments:

• Hospital

• Clinics

Research Methodology

Market Research Future analysis is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, competitive landscape (CL), and market penetration, as well as on emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories in different regions are estimated based on primary and secondary research.

Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets. The key players in the market were identified through secondary research, and their market contributions in the respective regions were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis by Market Research Future added before being presented in this report.

FOR MORE DETAILS https://www.wiseguyreports.com/reports/3861414-global-eye-cancer-ma...

Contact Us:

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)